Unicycive Therapeutics (UNCY) Long-Term Deferred Tax (2020 - 2022)

Unicycive Therapeutics (UNCY) has 3 years of Long-Term Deferred Tax data on file, last reported at $7.4 million in Q4 2022.

• For the quarter ending Q4 2022, Long-Term Deferred Tax rose 141.02% year-over-year to $7.4 million; the trailing twelve-month figure through Dec 2022 stood at $7.4 million (up 141.02% YoY), and the FY2022 full-year result was $7.4 million, up 141.02% from the prior year.
• Long-Term Deferred Tax for Q4 2022 stood at $7.4 million, up from $3.1 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $7.4 million in Q4 2022 and bottomed at $1.5 million in Q4 2020.
• The 3-year median for Long-Term Deferred Tax is $3.1 million (2021), against an average of $4.0 million.
• The widest annual swing landed in 2021, when Long-Term Deferred Tax jumped 111.81%; it then jumped 141.02% in 2022.
• A 3-year view of Long-Term Deferred Tax shows it stood at $1.5 million in 2020, then surged by 111.81% to $3.1 million in 2021, then surged by 141.02% to $7.4 million in 2022.
• The last three Long-Term Deferred Tax figures came in at $7.4 million (Q4 2022), $3.1 million (Q4 2021), and $1.5 million (Q4 2020), per Business Quant data.

Peer Comparison